

1:30 – 5:00 pm MSG project Steering Committee/investigators' meetings:

1:30 – 2 pm FOR-DMD – *R. Griggs/M.McDermott*

2 – 2:30 pm CMT trial - *M. Shy/R. Lewis*

2:30 – 3 pm MG-mycophenolate – *D. Sanders*

3 – 3:30 pm Arimoclomal Therapy for IBM - *R. Barohn*

3:30 – 4 pm Dermatomyositis – Etanercept investigators' meeting – *A. Amato*

4 – 4:30 pm SMA – *P. Kaufmann*

4:30 – 5 pm InQol – *M. Rose*

5- 6 pm Free Time

6 pm Social hour

7:00 pm Dinner

Friday, June 2, 2006

7:00 – 8 am Breakfast – *main lodge*

8:00 – 8:30 am Review of MSG Conflict of Interest Policy - *Auditorium – across from main lodge*

8:30 – 11:45 am **Translational Research in Neuromuscular Disease** – Moderator, Charles Thornton

8:30 – 9:00 am *Edward Kaye* - Regulatory approval for a neuromuscular treatment:
Lessons learned from Pompe Disease

9 – 9:30 am *Karl Kiebertz* - Perspectives on FDA reviews and approval process

9:30 – 10 am *Jerry Mendell* – *Therapeutic developments in Duchenne and Limb Girdle
muscular dystrophy*

10 – 10:30 am *Lee Sweeney* - Phase 1 clinical trials

10:30 -11 am *Duygu Selcen* - Myofibrillar myopathies

11: – 11:30 pm *Andrew Engel* – Congenital myasthenias

11:30-11:45 pm Panel Discussion

11:45 – 1 pm Lunch/Group Photo

1 – 1:15 pm NIH/NINDS Report – *John Porter*

1:15 – 1:30 pm NIH/NINDS Report on NIH-funded ALS trials – *Robin Conwit*

1:30 – 1:45 pm NIH/NIAMS Report – *Glen Nuckolls*

1:45 – 2 pm MDA Report – *Valerie Cwik*

2 – 3: 00 pm Investigator meetings (Continued):

HYP HOP Trial – *R. Griggs*

CINCH – *R. Griggs/B. Herr*